AbbVie and WuXi PharmaTech joined limited partners already including Eli Lilly, Pfizer and Johnson & Johnson to help the early-stage venture firm close its fourth fund.
US-based life science investment firm Accelerator Corporation closed its fourth fund at $62.8m yesterday after raising an additional $11.7m from pharmaceutical companies AbbVie and WuXi PharmaTech, and venture capital fund Watson Fund.
Accelerator had already raised capital from limited partners including pharmaceutical firms Eli Lilly, Pfizer and Johnson & Johnson, the latter two investing through their Pfizer Venture Investments and Johnson & Johnson Innovation – JJDC subsidiaries, Alexandria Venture Investments, Arch Venture Partners, Harris & Harris Group, Partnership Fund for…